Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain

Rheumatology International
Gustavo DezaFernando Gallardo

Abstract

Although several randomized clinical trials and observational studies have evaluated the effectiveness, safety and drug survival of etanercept (ETN) in the treatment of psoriatic arthritis (PsA), long-term data regarding these aspects are currently scarce. For this reason, we sought to investigate the long-term survival and safety of ETN in PsA patients in 4 tertiary care Spanish hospitals over a 13-year observation period (from 2004 to 2017). The records of 85 PsA patients were reviewed. ETN showed an excellent survival profile, with rates of treatment discontinuation at 1, 3, 5 and 10 years of 15, 37, 46 and 59%, respectively. In our cohort, a trend toward longer drug survival in patients with shorter disease duration and those who were treated with ETN as their first biologic agent was observed. On the other hand, combination therapy with conventional disease-modifying antirheumatic drugs did not provide greater improvement on the long-term drug survival. Only 12% of the patients reported adverse events (AEs) during therapy, being most of them of mild to moderate intensity, and in only 7% AEs led to drug discontinuation. To the best of our knowledge, the present study shows the largest follow-up period of ETN-treated populat...Continue Reading

References

Jul 13, 2004·Arthritis and Rheumatism·Philip J MeaseWayne Tsuji
Jan 29, 2005·Annals of the Rheumatic Diseases·C AntoniUNKNOWN IMPACT 2 Trial Investigators
Oct 4, 2005·Arthritis and Rheumatism·Philip J MeaseUNKNOWN Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group
Mar 2, 2006·Arthritis Research & Therapy·Juan J Gomez-ReinoUNKNOWN BIOBADASER Group
Jul 28, 2006·Arthritis and Rheumatism·William TaylorUNKNOWN CASPAR Study Group
Oct 28, 2008·Annals of the Rheumatic Diseases·C T RitchlinUNKNOWN Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Aug 19, 2010·The Journal of Rheumatology·Liisa M VirkkiDan C Nordström
Apr 9, 2013·Annals of the Rheumatic Diseases·Karen Minde FagerliTore K Kvien
Nov 17, 2014·The Journal of Rheumatology·Michael ZisapelOri Elkayam
Oct 18, 2015·Rheumatic Diseases Clinics of North America·Alexis Ogdie, Pamela Weiss
Dec 25, 2016·Seminars in Arthritis and Rheumatism·Kalle AaltonenDan Nordström

❮ Previous
Next ❯

Citations

Jul 9, 2020·Frontiers in Medicine·Kalliopi KlavdianouDimitrios Vassilopoulos
Jul 1, 2021·Rheumatology International·Lourdes Mateo SoriaAlejandro Olivé-Marqués

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.